Drug Criteria & Outcomes: In the pipeline
May 1, 2003 2 minutes read
Drug Criteria & Outcomes: In the pipeline
• Cardiome Pharma Corp. has commenced patient dosing of oxypurinol in a Phase II/III study of patients with congestive heart failure.
• SuperGen has announced that patient enrollment has been completed in an open-label, randomized Phase III clinical study of decitabine, an investigational treatment for advanced myelodysplastic syndrome.
• Telik has initiated a randomized, controlled Phase III registration trial of TLK286, administered as a single agent in ovarian cancer patients whose disease has progressed following platinum-based chemotherapy and one second-line treatment.
• Vion Pharmaceuticals has initiated a Phase I trial of Triapine, an inhibitor of ribonucleotide reductase, in combination with cytarabine (Ara-C) in patients with advanced leukemia.
• Barrier Therapeutics has announced that enrollment has begun in Phase III clinical trials for Seboride in both Europe and the United States. Seboride, a combination topical agent containing ketoconazole, an antifungal agent, and desonide, a steroid, is a patented gel formulation. The trials have been designed to show that the agent is effective in seborrheic dermatitis with a treatment regimen of once per day for two weeks.
• Schering AG, Berlin has announced that its novel experimental agent PTK787/ZK 222584, which is being developed in collaboration with Novartis AG, has entered Phase III clinical trials for treatment of metastatic colorectal cancer.
• Barrier Therapeutics has begun enrolling patients in its final Phase III clinical trial for its lead product, Zimycan, a topical ointment containing 0.25% of the antifungal miconazole, in a zinc oxide and petrolatum base. If approved, Zimycan would be the first and only product approved for use in Candida-associated diaper dermatitis.
• Access Pharmaceuticals has begun a Phase I clinical study to evaluate AP5346, a DACH Polymer Platinate. Upon successful completion of the Phase I study, a Phase IIA study will be conducted in ovarian cancer patients to determine the initial efficacy of AP5346.
The following drugs are in various stages of clinical studies and trials.You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content